Not Yet RecruitingPhase 4

Ketamine for the Treatment of Refractory Status Epilepticus

United States50 participantsStarted 2025-11

Plain-language summary

This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults 18 years of age or older
✓. Patients with refractory status epilepticus unresponsive to appropriately dosed first line agents administered intravenous or intraosseous and one second line agent
✓. First line agents: lorazepam, midazolam, or diazepam
✓. Second line agents: phenytoin (20 mg/kg), valproate (40 mg/kg), levetiracetam (60 mg/kg), lacosamide (400 mg)
✓. All etiologies of status epilepticus will be included

Exclusion criteria

✕. Exclusively psychogenic non epileptic seizures
✕. Pregnant individuals
✕. Incarcerated individuals
✕. Patients with hypersensitivity to ketamine or any component of the formulation
✕. Conditions in which an increase in blood pressure would be hazardous
✕. Focal motor status epilepticus
✕. Status epilepticus lasting \> 24 hours prior to enrollment (SRSE)
✕. Patients with EEG in the ictal-interictal continuum (IIC)

What they're measuring

Time to seizure cessation

Timeframe: 72 hours

Trial details

NCT IDNCT07177235

SponsorThomas Jefferson University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-07

Contact for this trial

Elizabeth Fletman, DO

215-955-7000 elizabeth.fletman@jefferson.edu

View on ClinicalTrials.gov More Refractory Status Epilepticus trials